Evaluating the effectiveness of one oral dose versus two oral doses of ivermectin in mass drug administration against scabies and tungiasis in Gamo zone, Southwest Ethiopia: a cluster randomized controlled trial
Phase 4
Recruiting
- Conditions
- Skin and Connective Tissue Diseases
- Registration Number
- PACTR202401655267670
- Lead Sponsor
- Arba Minch University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3782
Inclusion Criteria
All participants who are older than two years in the selected clusters are eligible to participate in the study.
Exclusion Criteria
Those individuals with an allergy to Ivermectin, treatment within the last 7 days with Ivermectin, pregnant women, breastfeeding women, and participants who decline treatment will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The prevalence of scabies
- Secondary Outcome Measures
Name Time Method ?The prevalence of tungiaisis<br>?The prevalence of impetigo <br>?The proportion of adverse events associated with oral ivermectin MDA within 14 days of intervention